Literature DB >> 20457613

Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization.

Hansen Wang1, Susan S Kim, Min Zhuo.   

Abstract

Fragile X syndrome, the most common form of inherited mental retardation, is caused by the absence of the RNA-binding protein fragile X mental retardation protein (FMRP). FMRP regulates local protein synthesis in dendritic spines. Dopamine (DA) is involved in the modulation of synaptic plasticity. Activation of DA receptors can regulate higher brain functions in a protein synthesis-dependent manner. Our recent study has shown that FMRP acts as a key messenger for DA modulation in forebrain neurons. Here, we demonstrate that FMRP is critical for DA D1 receptor-mediated synthesis of synapse-associated protein 90/PSD-95-associated protein 3 (SAPAP3) in the prefrontal cortex (PFC). DA D1 receptor stimulation induced dynamic changes of FMRP phosphorylation. The changes in FMRP phosphorylation temporally correspond with the expression of SAPAP3 after D1 receptor stimulation. Protein phosphatase 2A, ribosomal protein S6 kinase, and mammalian target of rapamycin are the key signaling molecules for FMRP linking DA D1 receptors to SAPAP3. Knockdown of SAPAP3 did not affect surface expression of alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) GluR1 receptors induced by D1 receptor activation but impaired their subsequent internalization in cultured PFC neurons; the subsequent internalization of GluR1 was also impaired in Fmr1 knock-out PFC neurons, suggesting that FMRP may be involved in subsequent internalization of GluR1 through regulating the abundance of SAPAP3 after DA D1 receptor stimulation. Our study thus provides further insights into FMRP involvement in DA modulation and may help to reveal the molecular mechanisms underlying impaired learning and memory in fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457613      PMCID: PMC2898437          DOI: 10.1074/jbc.M110.116293

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression.

Authors:  Lingfei Hou; Eric Klann
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

2.  BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal development.

Authors:  Gerhard M Schratt; Elizabeth A Nigh; Wen G Chen; Linda Hu; Michael E Greenberg
Journal:  J Neurosci       Date:  2004-08-18       Impact factor: 6.167

3.  Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D1 receptors.

Authors:  Yan-You Huang; Eleanor Simpson; Christoph Kellendonk; Eric R Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

4.  Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex.

Authors:  Guojun Chen; Paul Greengard; Zhen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

Review 5.  Translational regulatory mechanisms in persistent forms of synaptic plasticity.

Authors:  Raymond J Kelleher; Arvind Govindarajan; Susumu Tonegawa
Journal:  Neuron       Date:  2004-09-30       Impact factor: 17.173

6.  A proteasome-sensitive connection between PSD-95 and GluR1 endocytosis.

Authors:  Baris Bingol; Erin M Schuman
Journal:  Neuropharmacology       Date:  2004-10       Impact factor: 5.250

7.  Modulation of dopamine mediated phosphorylation of AMPA receptors by PSD-95 and AKAP79/150.

Authors:  Richard D Swayze; Marie-France Lisé; Joshua N Levinson; Anthony Phillips; Alaa El-Husseini
Journal:  Neuropharmacology       Date:  2004-10       Impact factor: 5.250

8.  Differential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse.

Authors:  Jeffrey M Welch; Dongqing Wang; Guoping Feng
Journal:  J Comp Neurol       Date:  2004-04-19       Impact factor: 3.215

Review 9.  The mGluR theory of fragile X mental retardation.

Authors:  Mark F Bear; Kimberly M Huber; Stephen T Warren
Journal:  Trends Neurosci       Date:  2004-07       Impact factor: 13.837

10.  Dopamine and protein phosphatase activity in renal proximal tubules.

Authors:  E Slobodyansky; Y Aoki; A K Gaznabi; D H Aviles; R D Fildes; P A Jose
Journal:  Am J Physiol       Date:  1995-02
View more
  26 in total

Review 1.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

2.  Molecular and genetic analysis of the Drosophila model of fragile X syndrome.

Authors:  Charles R Tessier; Kendal Broadie
Journal:  Results Probl Cell Differ       Date:  2012

3.  Tonic dopamine induces persistent changes in the transient potassium current through translational regulation.

Authors:  Edmund W Rodgers; Wulf-Dieter C Krenz; Deborah J Baro
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

4.  Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.

Authors:  Raehannah J Jamshidi; Laura C Sullivan; Blaine A Jacobs; Teresa A Chavera; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-07       Impact factor: 4.030

5.  Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome.

Authors:  Dilja D Krueger; Emily K Osterweil; Stephanie P Chen; Lynne D Tye; Mark F Bear
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

Review 6.  Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Authors:  Christina Gross; Elizabeth M Berry-Kravis; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

Review 7.  The pathophysiology of fragile X (and what it teaches us about synapses).

Authors:  Asha L Bhakar; Gül Dölen; Mark F Bear
Journal:  Annu Rev Neurosci       Date:  2012-04-05       Impact factor: 12.449

8.  Psychosis and catatonia in fragile X: Case report and literature review.

Authors:  Tri Indah Winarni; Andrea Schneider; Neera Ghaziuddin; Andreea Seritan; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2015-08

Review 9.  RNA-binding proteins, neural development and the addictions.

Authors:  C D Bryant; N Yazdani
Journal:  Genes Brain Behav       Date:  2016-01       Impact factor: 3.449

Review 10.  Dendritic protein synthesis in the normal and diseased brain.

Authors:  S A Swanger; G J Bassell
Journal:  Neuroscience       Date:  2012-12-20       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.